Is Tirzepatide a Peptide? The 39-Amino-Acid "Twincretin" Explained

Written by Nataliia Bondarchuk. Updated October 25, 2026.

Yes, tirzepatide is a peptide: a single chain of 39 amino acids that activates two gut-hormone receptors at once, GLP-1 and GIP, which is why it is called a dual agonist or "twincretin." Its backbone is based on the hormone GIP rather than GLP-1, with changes that let it also fit the GLP-1 receptor, and a 20-carbon fatty acid that binds to albumin so one injection lasts a week. At 39 amino acids it falls just under FDA's 40-amino-acid line between peptide drugs and biologics, which has practical consequences for how Zepbound and Mounjaro are made, copied and compounded.

This guide explains what a peptide is, how tirzepatide's structure produces its unusual two-hormone effect, how it compares with semaglutide and with the "peptides" sold online, and what being a peptide means for injections, storage, the coming pill, compounding and price.

A peptide is a short chain of amino acids linked by peptide bonds. Chemists generally call chains of up to about 50 amino acids peptides and longer chains proteins; FDA uses a hard cutoff of 40 for regulation, calling anything longer a protein and therefore a biologic. Many of the body's hormones are peptides: insulin (51 amino acids, at the border), GLP-1 (30 to 31), GIP (42), glucagon (29). Tirzepatide's 39 amino acids make it a peptide by both the chemist's and the regulator's definitions, three amino acids shorter than the GIP hormone it is modeled on.

Lilly's chemists started with GIP, which binds its own receptor tightly, and swapped in amino acids from GLP-1 and from exenatide at key positions until the molecule also activated the GLP-1 receptor well. The result is an "imbalanced" dual agonist: it is roughly as potent as natural GIP at the GIP receptor but about five times weaker than natural GLP-1 at the GLP-1 receptor, a balance that turned out to give more weight loss with less nausea than a pure GLP-1 drug at matched doses. Unlike semaglutide, whose backbone is grown in yeast, tirzepatide is made entirely by chemical peptide synthesis.

GLP-1 receptor activation lowers appetite, slows the stomach and boosts insulin when sugar is high. GIP receptor activation adds appetite suppression through a different brain pathway, improves how fat tissue stores and releases energy, and appears to blunt the nausea that GLP-1 causes, which lets the dose go higher. The combination is why tirzepatide produced 20.9% weight loss at 15 mg in SURMOUNT-1 versus about 15% for semaglutide 2.4 mg in its own trial, and 20.2% versus 13.7% head to head in SURMOUNT-5. The mechanism is explained in how Zepbound works and the comparison in tirzepatide vs semaglutide.

Peptides are exactly what the stomach and small intestine are built to digest, and a 4,800-dalton molecule cannot cross the gut wall on its own. A weekly injection under the skin avoids both problems. Lilly's answer to the pill question is not an oral tirzepatide but orforglipron, a small molecule that activates the GLP-1 receptor and can be swallowed; it does not touch the GIP receptor. See tirzepatide pill for where that stands. Within the injectable options, the drug is the same in the single-dose pen, the self-pay vials and the four-dose Zepbound KwikPen.

Sellers of unapproved peptides often list tirzepatide alongside BPC-157, CJC-1295 and ipamorelin as if they were the same kind of product. The chemistry is similar; nothing else is:

Structure explains how long it lasts; receptors explain what it does. Through GLP-1 and GIP receptors tirzepatide cuts hunger and cravings, slows gastric emptying, raises insulin when glucose is high and improves fat metabolism, producing 15% to 21% weight loss across the maintenance doses and large A1C reductions in diabetes. The dose ladder is in tirzepatide dosage for weight loss; the two brand names are compared in Mounjaro vs Zepbound.

If the brand names are confusing, see is Wegovy tirzepatide? Brand names explained for a side-by-side list of tirzepatide and semaglutide brands.

Tirzepatide is a 39-amino-acid peptide engineered from the GIP hormone to activate both the GIP and GLP-1 receptors, with a fatty acid that keeps it in the blood for a week. Being a peptide is why it is injected, refrigerated, regulated as a drug rather than a biologic, and briefly compounded during a shortage. It is also the only thing it has in common with the unapproved "peptides" sold online. For what comes after dual agonists, including the triple agonist retatrutide, see what comes after tirzepatide; for the side effects that follow from its receptors, see our side effects page.

This article is for general information and is not medical advice.